drugset / Trial / NCT05808881

Clinical Outcomes From Nalmefene

NCT05808881

Phase 4 Withdrawn Purdue Pharma LP
RandomizedParallel-groupOpen-labelTreatment

Summary

The purpose of this study is to assess the effectiveness of nalmefene relative to naloxone for the reversal of opioid intoxication in emergency department (ED) settings.

Timeline

Start
2023-06
Primary completion
2024-05
Completion
2024-05

Drugs

EvaluationDrugModalityDoseRoute
Subject Nalmefene Small molecule Intravenous
Comparator Naloxone Small molecule Intravenous